DJIA 18,080.14 21.45 0.12%
NASDAQ 5,092.09 36.02 0.71%
S&P 500 2,117.69 4.76 0.23%
market minute promo

Alnylam Pharmaceuticals (NASDAQ: ALNY)



company name or ticker

Cowen & Company Initiates Alnylam Pharmaceuticals With Outperform

Use Options For a Chance To Buy ALNY at a 36% Discount

Pharmacyclics Misses on Q4 Earnings, Reiterates 2015 View - Analyst Blog

Theravance Reports In Line Loss in Q4, Revenues Increase - Analyst Blog

Regeneron Beats on Q4 Earnings Driven by Eylea Sales (revised) - Analyst Blog

Hospira Launches Inflectra, Remicade Biosimilar, in Europe - Analyst Blog

Hospira Launches Inflectra, Remicade Biosimilar, in Europe - Analyst Blog

Company News for February 17, 2015 - Corporate Summary

Emergent BioSolutions Reports Positive Data on BioThrax - Analyst Blog

Emergent BioSolutions Reports Positive Data on BioThrax - Analyst Blog

2 Small Biotech Stocks Dreaming Big in Hepatitis C

Exciting but speculative -- Industry Focus examines two companies making strides in the treatment of hepatitis C.

Zacks Rank #1 Additions for Friday - Tale of the Tape

See More Articles...